Forum downsizing after Phase III schizophrenia miss

Forum Pharmaceuticals Inc. (Waltham, Mass.) said encenicline ( EVP-6124) missed the co-primary endpoints in two Phase III trials to treat cognitive impairment in schizophrenia (CIS). As a result, the company said it is restructuring.

The studies' co-primary endpoints were effect on cognitive function as evaluated by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Neurocognitive Composite Score, and effect on patient function as measured by the Schizophrenia Cognition Rating Scale (SCoRS). ...